Exosomal miR-181a-3p Regulates the Anlotinib Resistance of Lung Cancer Cells

This study investigates the mechanism of Anlotinib in the treatment of lung cancer drug resis-tance. A total of 30 lung cancer tissue specimens were retrospectively analyzed and 30 normal lung tissues were included as a control. Real-time PCR detected miR-181a-3p expression along with analysis of cell viability by MTT assay, cellinvasion by transwell, and the exosomal miR-181a-3p/UPR/ERAD signaling pathway. The expression of miR-181a-3p in peripheral blood of lung cancer was increased and the overall survival rate of patients with high miR-181a-3p in exosomes was shorter than patients with low expression.In A549 and H292 celllines, anlotinib is added to overex-press exosomal miR-181a-3p, cell viability and invasion were significantly increased. After knocking down exosomal miR-181a-3p, cell viability and invasion were significantly reduced. The expression of miR-181a-3p is directly regulated by exosomes UPR/ERAD. After overexpression of exosomes miR-181a-3p, the protein levels of UPR and ERAD were significantly reduced and increased after knockdown of exosomes miR-181a-3p.In conclusion, the secretory miR-181a-3p/UPR/ERAD path-way promotes the proliferationof A549and H292 cells, reulatestheresistance of Anlotinib, and IP:203.8.109.20On: Thu, 11 Aug 2022 09:03:31 can increase the resistanceflungcancer toAnlotinibbypromotingthe proliferation signaling Copyright: American Scientific Publishers pathway, and promote the growth of tumorcells. Delivered by Ingenta